Repatha dosing schedule

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Repatha Dosing Schedule: An Overview

Introduction to Repatha (Evolocumab)

Repatha, also known by its generic name evolocumab, is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This medication is primarily used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia, including those with familial hypercholesterolemia 13.

Standard Dosing Schedule

Biweekly Dosing

One of the standard dosing schedules for Repatha involves administering 140 mg subcutaneously every two weeks. This regimen has been shown to significantly reduce LDL-C levels in various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and both heterozygous and homozygous familial hypercholesterolemia 13.

Monthly Dosing

Alternatively, Repatha can be administered at a dosage of 420 mg once monthly. This dosing schedule offers a similar efficacy in lowering LDL-C levels and provides flexibility for patients who may prefer less frequent injections 134.

Efficacy and Safety

LDL-C Reduction

Clinical trials have demonstrated that Repatha, whether administered biweekly or monthly, can reduce LDL-C levels by approximately 50-60% from baseline when added to statin therapy or used as monotherapy in statin-intolerant patients 134. This significant reduction in LDL-C is consistent across various patient groups, including those with high cardiovascular risk .

Long-term Efficacy and Safety

The long-term efficacy and safety of Repatha have been evaluated in controlled trials lasting from 12 to 76 weeks. These studies indicate that Repatha is well-tolerated and maintains its efficacy over extended periods 13. However, the long-term impact on cardiovascular outcomes remains to be fully established .

Conclusion

Repatha offers a flexible and effective treatment option for lowering LDL-C levels in patients with hyperlipidemia. The biweekly 140 mg and monthly 420 mg dosing schedules provide significant reductions in LDL-C, making it a valuable addition to lipid-lowering therapies, especially for patients who are unable to achieve their LDL-C goals with statins alone or who are statin-intolerant.

Sources and full results

Most relevant research papers on this topic

Evolocumab: A Review in Hyperlipidemia

Evolocumab is a valuable new treatment for primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia, particularly in patients unable to reach LDL-C goals despite statins and those who cannot tolerate or receive statins.

Very Rigorous Journal

2016·

14citations

·G. Keating

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.

Mealtime dosing with repaglinide effectively improves glycemic control in type 2 diabetic patients, regardless of meal patterns, without compromising control or increasing the risk of adverse events.

RCTLarge Human TrialHighly Cited

2001·

70citations

·R. Moses et al.

[Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].

Evolocumab effectively reduces LDL-C levels by 50-60% when added to statins, and is a promising treatment for patients with heterozygous and homozygous familial hypercholesterolemia.

2017·

1citation

·C. Wallemacq

Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.

Evolocumab (Repatha) is a second PCSK9 inhibitor that can lower LDL-cholesterol levels by 60% in high-risk patients already taking maximal statin therapy, but long-term efficacy and safety are unknown and expensive.

2015·

4citations

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.

High-dose medroxyprogesterone acetate shows a higher response rate in postmenopausal women with advanced breast cancer, making it an ideal second-line treatment option.

RCTHighly Cited

1984·

81citations

·F. Cavalli et al.

Treatment of tuberculosis and optimal dosing schedules

Daily tuberculosis treatment regimens are highly recommended to reduce the risk of treatment failure, recurrence, and drug resistance, particularly in the initial phase.

Systematic ReviewRigorous Journal

2010·

53citations

·K. Chang et al.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Dose-intense chemotherapy reduces breast cancer recurrence and mortality rates, but may increase the risk of death without recurrence.

Meta-AnalysisRigorous JournalHighly Cited

2019·

265citations

·Richard Rosie Jeremy Zulian Richard Lucy David Paul Hongch Gray Bradley Braybrooke Liu Peto Davies Dodwell Mc et al.

Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.

Buprenorphine treatment for opioid dependence is equally effective with daily, twice, or thrice weekly dosing, promoting treatment retention and reducing HIV risk behavior.

RCTHighly Cited

2005·

76citations

·L. Marsch et al.

Clinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis

Repatha effectively reduces blood lipids and prevents coronary atherosclerosis in patients with hyperlipidemia, without affecting cognitive function.

2022·

0citations

·Yongzhe Li

Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.

Alternate-day dosing with buprenorphine is effective and acceptable for a substantial portion of patients with opioid dependence, but daily dosing may have superior clinical efficacy.

RCTHighly Cited

1995·

94citations

·Rolley E. Johnson et al.

Try another search

air pollution facts

copd exacerbation

simvastatin 40 mg side effects

prednisolone and metformin

rectal cancer symptoms male

good cholesterol versus bad